Clinical Trial Search

Primary: Percentage of Participants Achieving the Immunoglobulin G (IgG) Serotype-specific ≥0.35 μg/mLThreshold Value for Postvaccination 3 — 98.0; 96.2; 97.5; 93.3 Percentage of…

Primary: For Participants in the PK Lead-in Phase, Pharmacokinetic (PK) Parameter: AUCtau of GS-331007 (Metabolite of SOF) — 9106.0; 7651.2; 10293.7 h*ng/mL

Primary: Glucose — 7.1; 6.4 mmol/L

Primary: Change in Premature Atrial Contractions (PACs) — -0.6; -5.6 Episodes/hour

Primary: The Sensitivity of Detecting RCC Recurrence (Using Contrast-enhanced MRI as a Reference Standard) on a Single Contrast-enhanced Ultrasound Exam. — 100 percent of patients

Primary: Percentage of Adult Participants Experiencing ≥1 Adverse Event (AE) — 100.0; 100.0 Percentage of Participants

Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 1 Participants

Primary: Variation of the Concentration of Phleum Pratense Extract Needed to Produce a Positive Nasal Provocation Test From Baseline (V0) to Final Visit (FV). — 0.493; 0.275…

Primary: Number of Participants With Intraocular Inflammation — 6; 10 Participants

Primary: Unified Parkinson's Disease Rating Scale-Part III (UPDRS-III) Change From Baseline at Week 24 — -0.55; 1.45; -1.29 units on a scale — p=0.158

Primary: Progression Free Survival With the Combination of GDC-0449 With Gemcitabine and Nab-paclitaxel. — 5.42 months

Primary: Percentage of Participants With Non-functioning Pituitary Adenomas (NFPA) Who Achieve Tumor Volume Reduction of at Least 20% After 24 Weeks (FAS) — 16.7 percentage of…

Primary: Proportion of Patients Without a Progression Free Survival Event at 4 Months (PFS4) — .323; .267 proportion of participants — p=0.70

Primary: Von Kossa Staining Per Unit Area of Dermis — -0.0033; 0.0010; 0.0087; 0.0123 microns

Primary: Number of Participants With Treatment Emergent Adverse Events — 2; 1; 3; 1 Participants